Synmosa Biopharma (ROCO:4114) Other Current Receivables: NT$108 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4114 Synmosa Biopharma Corp ROCO:4114
83 GF Score
Price NT$28.95
GF Value NT$32.87
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Synmosa Biopharma Other Current Receivables?

Synmosa Biopharma ROCO:4114 -0.34% 83 Other Current Receivables is NT$108 Mil as of Mar. 2026. GuruFocus rates ROCO:4114 with a GF Score™ of 83/100 and a GF Value™ of NT$32.87 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Synmosa Biopharma's Other Current Receivables for the quarter that ended in Mar. 2026 was NT$108 Mil.

Synmosa Biopharma's quarterly Other Current Receivables declined from Sep. 2025 (NT$114.80 Mil) to Dec. 2025 (NT$94.92 Mil) but then increased from Dec. 2025 (NT$94.92 Mil) to Mar. 2026 (NT$108.44 Mil).

Synmosa Biopharma's annual Other Current Receivables declined from Dec. 2023 (NT$134.78 Mil) to Dec. 2024 (NT$98.33 Mil) and declined from Dec. 2024 (NT$98.33 Mil) to Dec. 2025 (NT$94.92 Mil).

Synmosa Biopharma Other Current Receivables Related Terms

Synmosa Biopharma Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Synmosa Biopharma's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synmosa Biopharma Other Current Receivables Chart

Synmosa Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 95.40 141.99 134.78 98.33 94.92

Synmosa Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.33 85.41 114.80 94.92 108.44
ROCO:4114
83GF Score
Synmosa Biopharma Corp ROCO:4114
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Synmosa Biopharma Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of NT$108 Mil mean?
Synmosa Biopharma (ROCO:4114) has a Other Current Receivables of NT$108 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Synmosa Biopharma and its competitors.
Is Synmosa Biopharma's Other Current Receivables too high?
Synmosa Biopharma's current Other Current Receivables is NT$108 Mil. Overall, Synmosa Biopharma has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's Other Current Receivables compare to ZTS?
Synmosa Biopharma's Other Current Receivables of NT$108 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Synmosa Biopharma and its competitors. Synmosa Biopharma's current Other Current Receivables is NT$108 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$32.87, compared to a current price of NT$28.95 — trading 11.9% below its estimated fair value. The current Other Current Receivables is NT$108 Mil. Synmosa Biopharma's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current Other Current Receivables is NT$108 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?

Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued. The current stock price of NT$28.95 is trading 11.9% below its estimated GF Value™ of NT$32.87. GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.

Key valuation signals for ROCO:4114:

  • Other Current Receivables: NT$108 Mil
  • GF Value™: NT$32.87 vs. price of NT$28.95 (11.9% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synmosa Biopharma Business Description

Address No. 6, Gongye 1st Road, Hukou Township, Hsinchu County, Hsinchu, TWN
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
83GF Score

Get the complete analysis for ROCO:4114

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$28.95
Price
NT$32.87
GF Value